 |
2-(1,1-difluoroethyl)-5-methyl-N-[4-(pentafluoro-�{6}-sulfanyl)phenyl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine |
|---|---|
| Trade Name | |
| Orphan Indication | Malaria |
| USA Market Approval | USA |
| USA Designation Date | 2017-08-18 00:00:00 |
| Sponsor | Paul Maher, MD;10644 Weymouth Street, Suite 104;Bethesda, Maryland, 20814 |
